Research News And Discoveries
-
A potential new targeted therapy for metastatic melanoma
By Wendy Bindeman https://cdn.vanderbilt.edu/t2-main/medschool-prd/wp-content/uploads/sites/101/2020/08/Discovery_Richmond-SMWeb-1.mp4 Melanoma is the most common of all cancers. The American Cancer Society estimates that over 100,000 new melanomas will be diagnosed in the U.S. in 2020. While 60 percent of people with metastatic melanoma, an aggressive type of skin cancer, have multiple treatment options… Read MoreAugust 19, 2020
-
Vanderbilt University School of Medicine Basic Sciences announces eight new additions to its Board of Visitors
By Zoe Weinman The Board of Visitors of Vanderbilt University School of Medicine Basic Sciences, established in 2018, recently added eight new members. The board consists of alumni and non-alumni who have expertise in fields related to basic sciences research, education and career development. These experts act as advisors to… Read MoreAugust 19, 2020
-
The importance of estrogen cycles
Aug. 6, 2020, 10:00 AM by Sarah Glass Oral contraceptives are implicated in slightly increasing breast cancer risk. This birth control method contains forms of estrogen, a hormone that binds ERalpha (estrogen receptor alpha), to alter the reproductive cycle. While much is known about estrogen signaling, few have researched how receptor homeostasis… Read MoreAugust 6, 2020
-
Siciliano wins Fay/Frank Seed Grant and Alkermes Pathways Research Award
Aug. 5, 2020, 7:00 AM By Jenna Somers Cody Siciliano (Vanderbilt University) Assistant Professor of Pharmacology Cody Siciliano has been awarded the Fay/Frank Seed Grant from the Brain Research Foundation and the Alkermes Pathways Research Award from the… Read MoreAugust 5, 2020
-
Protein study may be key to treating fibrotic diseases
Jul. 30, 2020, 8:08 AM by Bill Snyder A protein linked to amyotrophic lateral sclerosis (ALS), a progressive neurological disease that causes muscle weakness, may be a key to treating fibrotic disease of the kidneys and other organs, researchers at Vanderbilt University Medical Center reported recently. FUS is the… Read MoreJuly 31, 2020
-
Discovery of a brain ‘negative regulator’ alters understanding of brain function and potential treatment of cognitive disorders
by Marissa Shapiro Jul. 21, 2020, 10:00 AM The brain has an uncanny ability to enhance or reduce communication between brain cells. Whether or not communication is fast or slow changes the brain’s overall function. Understanding how these cells communicate within the brain is… Read MoreJuly 23, 2020
-
Vanderbilt bioengineer’s trailblazing cancer research receives $1M W. M. Keck Foundation grant
A bold engineering approach by a Vanderbilt University researcher to sort breast cancer cells based on their behavior first has produced compelling data that show less migratory cells create more metastases, contradicting the prevailing hypothesis on how cancer spreads. Expanding this ambitious research by Cynthia Reinhart-King, Cornelius Vanderbilt Professor… Read MoreJuly 17, 2020
-
Richmond steps down as associate director for Research Education for VICC
Jul. 16, 2020, 9:16 AM by Tom Wilemon After serving 16 years as associate director for Research Education at Vanderbilt-Ingram Cancer Center (VICC), Ann Richmond, PhD, Ingram Professor of Cancer Research, is stepping down from the leadership post. Ann Richmond, PhD, is stepping down from her role as associate director… Read MoreJuly 17, 2020
-
Antibody research at Vanderbilt University Medical Center shows promise in fight against COVID-19
Jul. 15, 2020, 1:42 PM by Bill Snyder Based on positive results in preclinical studies reported today, potently neutralizing antibodies identified by researchers at Vanderbilt University Medical Center are showing promise as a potential therapy for preventing and treating COVID-19. The monoclonal antibodies were isolated from the blood of a couple… Read MoreJuly 17, 2020
-
VUMC studies provide key positive results for COVID-19 vaccine in early-stage clinical trial
Jul. 14, 2020, 4:19 PM by Leigh MacMillan An experimental coronavirus vaccine stimulated robust immune responses against SARS-CoV-2, the virus that causes COVID-19, and raised no serious safety concerns in an early-stage clinical trial. The vaccine, called mRNA-1273, was developed by Moderna Inc. in collaboration with the National Institute of… Read MoreJuly 17, 2020